We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$2.6B
AUM Growth
-$20.1M
Cap. Flow
-$117M
Cap. Flow %
-4.48%
Top 10 Hldgs %
41.28%
Holding
99
New
18
Increased
10
Reduced
56
Closed
6

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.3M
2
ALXO icon
ALX Oncology
ALXO
+$38.2M
3
OMER icon
Omeros
OMER
+$28.6M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.9M
5
ZYME icon
Zymeworks
ZYME
+$20.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$95.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.8M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$23M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.6M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
2 Miscellaneous 12.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
51
uniQure
QURE
$2.98B
$12M 0.46%
325,000
-119,157
-27% -$4.88M
SRPT icon
52
Sarepta Therapeutics
SRPT
$2.13B
$11.9M 0.46%
85,000
-25,000
-23% -$3.8M
INSM icon
53
Insmed
INSM
$26.8B
$11.2M 0.43%
350,000
-100,000
-22% -$2.87M
AKUS
54
DELISTED
Akouos Inc
AKUS
$11.2M 0.43%
499,991
+1
+0% +$22
RPTX
55
DELISTED
Repare Therapeutics
RPTX
$10.7M 0.41%
348,567
-4,228
-1% -$112K
ARGX icon
56
argenx
ARGX
$61.7B
$10.5M 0.4%
40,000
-30,000
-43% -$7.21M
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
$10.3M 0.4%
50,000
-22,510
-31% -$5.83M
OMER icon
58
CALL
Omeros
OMER
$1.28B
$10.1M 0.39%
+1,000,000
New +$12.9M
HARP
59
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.69M 0.37%
57,060
-7,466
-12% -$1.08M
TBPH icon
60
Theravance Biopharma
TBPH
$885M
$9.61M 0.37%
650,072
+550,072
+550% +$10.3M
ANAB icon
61
AnaptysBio
ANAB
$1.61B
$9.59M 0.37%
650,000
-235,838
-27% -$4.25M
OBIO icon
62
Orchestra BioMed
OBIO
$368M
$8.8M 0.34%
+800,000
New +$8.98M
ITOS
63
DELISTED
iTeos Therapeutics
ITOS
$8.63M 0.33%
+350,000
New +$9.41M
TNGX icon
64
Tango Therapeutics
TNGX
$4.02B
$8.37M 0.32%
+800,000
New +$8.17M
TARA icon
65
Protara Therapeutics
TARA
$218M
$7.57M 0.29%
+450,000
New +$10.4M
PNT
66
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.19M 0.28%
+500,000
New +$6.82M
MORF
67
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.83M 0.26%
+250,000
New +$6.55M
TCDA
68
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.59M 0.25%
727,975
-144,162
-17% -$2.11M
ALLK
69
DELISTED
Allakos
ALLK
$6.11M 0.23%
75,000
-122,515
-62% -$9.95M
GTH
70
DELISTED
Genetron Holdings Limited ADS
GTH
$5.97M 0.23%
166,667
– –
AVEO
71
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.94M 0.23%
1,000,000
-350,000
-26% -$1.73M
FSDC
72
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$5.6M 0.22%
+500,000
New +$5.35M
SRNE
73
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$5.58M 0.21%
+500,000
New +$4.58M
MRUS
74
DELISTED
Merus
MRUS
$5.15M 0.2%
429,284
-170,716
-28% -$2.2M
QTTB icon
75
Q32 Bio
QTTB
$330M
$5.04M 0.19%
26,161
-4,395
-14% -$985K
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Cormorant Asset Management held 99 positions worth $2.6B, down 0.77% from $2.62B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $117M in Q3 2020, closing 6 positions and reducing 56 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $95.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Immunovant worth $57.6M.

  • Cormorant Asset Management's largest Q3 2020 buy was Immunovant: 1,637,951 shares worth $57.6M.
  • Cormorant Asset Management added most to Omeros in Q3 2020, an estimated $28.6M increase.
  • Cormorant Asset Management's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.8M.
  • Cormorant Asset Management fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $95.1M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $2.6B portfolio in Q3 2020.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q3 2020.
  • Cormorant Asset Management's portfolio value fell 0.77% quarter-over-quarter to $2.6B.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.